Could a common Parkinson's pill help treat wet AMD?
NCT ID NCT03022318
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested carbidopa-levodopa (Sinemet), a drug usually used for Parkinson's disease, in 20 people with wet age-related macular degeneration (AMD). The goal was to see if the drug is safe and can improve vision or reduce retinal swelling. Participants took the pill for a short time, and researchers measured changes in eyesight and eye scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carbidopa-levodopa (Sinemet)
What this could lead to
If it works, this could point toward a new oral treatment for wet AMD, potentially reducing the need for frequent eye injections.
What could go wrong
This is a very small, early-phase trial with only 20 participants. The drug may not improve vision or could cause side effects like nausea or dizziness. Results may not apply to everyone with AMD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Robert W Snyder, MD, PhD, PC
Tucson, Arizona, 85712, United States